Applications of (S)-3-(Boc-Amino)-4-Phenylbutyric Acid in Industrial Manufacturing

As the direct manufacturer of (S)-3-(Boc-Amino)-4-Phenylbutyric Acid, we support pharmaceutical, biotech, and advanced chemical production with high-purity material. Our supply integrates into precise industrial processes across select specialization tracks, each with strict compliance and manufacturing demands. Outlined below are specific application scenarios with detailed notes on standards, usage, process placement, and typical finished products for our customers worldwide.

1. Chiral Intermediate for Angiotensin II Receptor Antagonist APIs

(S)-3-(Boc-Amino)-4-Phenylbutyric Acid serves as a key chiral building block in the multi-stage synthesis of angiotensin II receptor antagonists, especially the active pharmaceutical ingredient (API) in antihypertensive drugs. Manufacturers typically employ it in asymmetric synthesis steps, integrating this amino acid derivative during intermediate coupling reactions. Its protected amine function helps achieve correct stereoselectivity in peptidomimetic structures, ensuring regulatory-grade purity for downstream API release.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice (GMP) for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) monographs on related intermediates
• US FDA 21 CFR part 211 for finished pharmaceuticals
• China Pharmacopoeia for chiral intermediates (where locally registered)

Typical usage ratio

• Generally 1.0–1.3 molar equivalents relative to coupling partner; exact ratio adjusted based on enantiopurity and impurity profile in batch scale-up

Downstream process integration

• Added in the protected form to peptide coupling or amidation step
• Deprotection under acidic conditions post-coupling
• Followed by extraction and purification prior to final API coupling or hydrogenation

Final product types

• Losartan potassium, irbesartan, candesartan, other sartan-class APIs
• Regulated antihypertensive drug substances

2. Peptidomimetic Drug Intermediate Synthesis

Pharmaceutical R&D and contract manufacturing organizations (CMOs) utilize (S)-3-(Boc-Amino)-4-Phenylbutyric Acid in the assembly of peptidomimetic scaffolds. This compound’s Boc-protected amine and phenylbutyric backbone make it a strategic selection for introducing conformational constraints within target molecules designed to inhibit proteases or act as receptor modulators. It enables efficient solid-phase and solution-phase synthesis workflows, maintaining stereochemical control and batch reproducibility.

Industry compliance standards

• US FDA DMF submission and annual GMP audit for APIs/Intermediates
• European Medicines Agency (EMA) guidelines for chemical purity and genotoxic impurities
• ICH Q3A/Q3C guidelines for impurities and solvent use

Typical usage ratio

• Normally 0.9–1.2 equivalents per peptide chain elongation step
• Adjusted up or down based on the scale of peptide library synthesis and resin loading in solid-phase approaches

Downstream process integration

• Coupled as a protected amino acid in automated or manual peptide synthesizers
• Integrated into iterative chain elongation protocols
• Boc group removed with TFA during final deprotection phase before crude purification

Final product types

• Peptidomimetic drug candidates for clinical trials
• Research-grade bioactive peptides for preclinical screening

3. Stereospecific Intermediate for CNS Active Small Molecule Synthesis

The compound offers reliable chirality for the synthesis of certain central nervous system (CNS) active small molecules, including γ-aminobutyric acid (GABA) analogues. Medicinal chemists and process development groups select this acid to introduce chiral side chains, controlling configuration during key condensation steps. Regulatory documentation typically covers both the intermediate and traceability up to the final API, requiring validated routes and impurity assessment under cGMP.

Industry compliance standards

• US FDA ICH Q11 guidelines for drug substance manufacturing
• WHO Good Manufacturing Practice (GMP) for APIs
• Certificate of Suitability (CEP) for EMA-regulated markets

Typical usage ratio

• Applied at 1.0–1.2 molar equivalents in amide bond-forming transformations
• Process-specific tuning according to content of side-product and scale (pilot or commercial)

Downstream process integration

• Introduced in stereocontrolled condensation phase after initial backbone assembly
• Boc amine protection remains until late-stage deprotection just prior to final product crystallization

Final product types

• Baclofen derivatives
• Advanced CNS pharmaceutical research intermediates

4. Advanced Intermediate in Specialty Chemical Synthesis for Biotech Research

Leading biotech firms and research reagent producers integrate (S)-3-(Boc-Amino)-4-Phenylbutyric Acid within the synthesis of specialty building blocks used for biochemical assay kits, labeling reagents, and custom probe molecules. The compound’s protected amine functionality allows strategic functionalization at varied positions, supporting both batch and semi-continuous processing. Process teams closely monitor residual Boc and phenyl content to meet stringent final product QC requirements for analytical use.

Industry compliance standards

• ISO 9001:2015 for quality management systems
• REACH registration for import to EU
• US Environmental Protection Agency (EPA) TSCA requirements for new chemical substances (where applicable)

Typical usage ratio

• 0.8–1.5 equivalents per synthetic step, depending on the intended downstream modification
• Adjusted per customer-specific route and final assay sensitivity target

Downstream process integration

• Added as protected amino acid in side-chain modification sequence
• Processed in flow chemistry modules or batch reactors prior to downstream functional group introduction

Final product types

• Bioactive labeling probes
• Reagent kits and high-purity research chemicals for analytical markets